Tier 2 — strong

Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction

Wang DD, Airhart SE, Zhou B, Shireman LM, Jiang S, Melendez Rodriguez C, Kirkpatrick JN, Shen DD, Tian R, O'Brien KD
JACC. Basic to translational science 2022 7; 12; 1183-1196

Bibliography

PubMed
PMID 36644285
PubMed Central
PMC9831861
DOI
10.1016/j.jacbts.2022.06.012
Funding
NIH/NHLBI, American Heart Association and John L. Locke Jr. Foundation support. ChromaDex supplied NR and placebo without funding the trial.
Competing interests
One author reported Cytokinetics advisory-board membership; the paper separately disclosed industry product supply.

Study snapshot

DesignRandomized placebo-controlled human trial
ModelHuman participants
Sample30 adults with stable reduced-ejection-fraction heart failure
InterventionNR titrated to 1000 mg twice daily versus placebo
Duration12-week clinical trial
EndpointsSafety; blood NAD+; PBMC respiration

What the study showed, in plain terms

NR was generally tolerated and approximately doubled whole-blood NAD+. NAD+ changes correlated with selected immune-cell respiration and inflammatory measures.

Key findings

NR was generally tolerated and approximately doubled whole-blood NAD+. NAD+ changes correlated with selected immune-cell respiration and inflammatory measures.

What this study can and cannot tell us

A small safety-focused trial; correlations in blood cells do not establish improved cardiac function, fewer admissions or survival.

Related papers in the corpus

Tier 4
Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure
Zhou B et al. · The Journal of clinical investigation · 2020

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology